SMSPHARMA · NSE
SMS Pharmaceuticals Limited
₹442.95
+7.06% (+₹29.2)
Prev. close
₹413.75
Volume
17,45,125
Delivery %
31.5%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. It offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The company exports its products to approximately 75 countries. SMS Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Ramesh Babu Potluri
Headquarters
Hyderabad
Employees
1,617
Website
smspharma.comExchange
View on NSE ↗Key stats
Market cap
₹4,141.29 Cr
P/E ratio (TTM)
38.9
Dividend yield
0.10%
EPS (TTM)
₹11.38
Beta (1Y · daily vs NIFTY 50)
1.30
Beta (5Y · monthly vs NIFTY 50)
1.38
Shares float
2.24 Cr
EPS · quarter ended Jun 2026
₹2.23
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.4% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹563.18 Cr | ₹519.87 Cr | ₹522.05 Cr | ₹709.26 Cr | ₹782.75 Cr | ₹886.87 Cr | |
| EBITDA | ₹124.56 Cr | ₹119.53 Cr | ₹59.39 Cr | ₹121.08 Cr | ₹145.22 Cr | ₹179.63 Cr |
| ₹62.53 Cr | ₹62.22 Cr | ₹-7.06 Cr | ₹49.83 Cr | ₹69.14 Cr | ₹101.99 Cr | |
| Diluted EPS | ₹7.39 | ₹7.35 | ₹-0.83 | ₹5.89 | ₹8.16 | ₹11.15 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹812.21 Cr | ₹859.50 Cr | ₹879.61 Cr | ₹1,034.09 Cr | ₹1,152.68 Cr | ₹1,362.44 Cr | |
| — | ₹263.27 Cr | ₹254.07 Cr | ₹280.77 Cr | ₹310.76 Cr | ₹365.05 Cr | |
| Stockholders' equity | ₹410.53 Cr | ₹470.29 Cr | ₹460.53 Cr | ₹536.33 Cr | ₹639.64 Cr | ₹785.81 Cr |
Fixed assets, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹106.50 Cr | ₹40.23 Cr | ₹22.45 Cr | ₹50.12 Cr | ₹81.71 Cr | ₹59.22 Cr | |
| Investing cash flow | ₹-151.59 Cr | ₹-27.15 Cr | ₹-29.69 Cr | ₹-52.07 Cr | ₹-123.43 Cr | ₹-130.78 Cr |
| ₹75.97 Cr | ₹-6.92 Cr | ₹-31.97 Cr | ₹30.68 Cr | ₹47.08 Cr | ₹76.03 Cr | |
| Capital expenditure | ₹-151.75 Cr | ₹-27.25 Cr | ₹-30.02 Cr | ₹-52.16 Cr | ₹-123.38 Cr | ₹-130.56 Cr |
| End cash position | ₹40.42 Cr | ₹46.58 Cr | ₹7.38 Cr | ₹36.04 Cr | ₹41.40 Cr | ₹45.88 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 19–Mar 22(5Q) | Jun 22–Dec 22(3Q) | Mar 23 | Jun 23–Dec 23(3Q) | Mar 24–Dec 24(4Q) | Mar 25–Jun 25(3Q) | Sep 25–Jun 26(5Q) |
|---|---|---|---|---|---|---|---|
| Promoter | 67.29% | 64.17% | 64.29% | 64.32% | 64.67% | 66.26% | 68.07% |
| Public | 32.71% | 35.83% | 35.71% | 35.68% | 35.33% | 33.74% | 31.93% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| SMS Pharmaceuticals Limited | ₹4,141.29 Cr | ₹442.95 | 38.9 | 5.27 | 13.0% | 0.46 | +13.3% | +55.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Show all 22
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
SMS Pharmaceuticals Share Price news: stock gains 11.62%
SMS Pharmaceuticals shares rose 11.62% to Rs 438.35, with a market capitalization of Rs 3,677.72 crore. The stock's significant intraday gain occurred without a confirmed company-specific catalyst. Investors are advised to consider fundamentals and sector positioning rather than unverified triggers.